MX2023001596A - Métodos para enriquecer células t diseñadas genéticamente. - Google Patents

Métodos para enriquecer células t diseñadas genéticamente.

Info

Publication number
MX2023001596A
MX2023001596A MX2023001596A MX2023001596A MX2023001596A MX 2023001596 A MX2023001596 A MX 2023001596A MX 2023001596 A MX2023001596 A MX 2023001596A MX 2023001596 A MX2023001596 A MX 2023001596A MX 2023001596 A MX2023001596 A MX 2023001596A
Authority
MX
Mexico
Prior art keywords
methods
genetically engineered
enrich
cells
relate
Prior art date
Application number
MX2023001596A
Other languages
English (en)
Inventor
Carsten Linnemann
Thomas Kuilman
Gavin M Bendle
Heijst Jeroen W J Van
Xiangjun Kong
Original Assignee
Neogene Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neogene Therapeutics B V filed Critical Neogene Therapeutics B V
Publication of MX2023001596A publication Critical patent/MX2023001596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se divulgan diversas modalidades relacionadas con métodos para la selección de una célula diseñada genéticamente. Algunas modalidades se refieren a una célula que se produce con los métodos descritos en el presente documento.
MX2023001596A 2020-08-07 2021-08-05 Métodos para enriquecer células t diseñadas genéticamente. MX2023001596A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063062854P 2020-08-07 2020-08-07
US202163135460P 2021-01-08 2021-01-08
US202163170269P 2021-04-02 2021-04-02
US202163221808P 2021-07-14 2021-07-14
PCT/US2021/071122 WO2022032299A1 (en) 2020-08-07 2021-08-05 Methods to enrich genetically engineered t cells

Publications (1)

Publication Number Publication Date
MX2023001596A true MX2023001596A (es) 2023-04-20

Family

ID=77543729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001596A MX2023001596A (es) 2020-08-07 2021-08-05 Métodos para enriquecer células t diseñadas genéticamente.

Country Status (10)

Country Link
US (1) US20220041999A1 (es)
EP (1) EP4192941A1 (es)
JP (1) JP2023537048A (es)
KR (1) KR20230065251A (es)
CN (1) CN116323920A (es)
AU (1) AU2021320556A1 (es)
CA (1) CA3188431A1 (es)
MX (1) MX2023001596A (es)
TW (1) TW202212352A (es)
WO (1) WO2022032299A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022183076A1 (en) * 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Enhanced immune cell therapy targeting ny-eso-1
EP4433577A1 (en) 2021-11-15 2024-09-25 Neogene Therapeutics B.V. Engineered t cells with reduced tgf-beta receptor signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009181A (es) * 2015-01-26 2017-11-22 Cellectis Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
CN109790517B (zh) * 2016-04-15 2023-05-02 纪念斯隆-凯特林癌症中心 转基因t细胞和嵌合抗原受体t细胞组合物和相关方法
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CN107201365B (zh) * 2017-05-19 2018-04-20 四川丰讯科技发展有限公司 一种特异性敲除二氢叶酸还原酶基因的sgRNA序列及其应用
WO2019018553A1 (en) * 2017-07-18 2019-01-24 The Broad Institute, Inc. METHODS OF PRODUCING HUMAN CANCER CELL MODELS AND METHODS OF USE
US20200224160A1 (en) * 2018-02-27 2020-07-16 Sorrento Therapeutics, Inc. Process for dna integration using rna-guided endonucleases
EP3781176A4 (en) * 2018-04-09 2022-05-25 The Trustees of the University of Pennsylvania METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR

Also Published As

Publication number Publication date
TW202212352A (zh) 2022-04-01
US20220041999A1 (en) 2022-02-10
WO2022032299A1 (en) 2022-02-10
CN116323920A (zh) 2023-06-23
JP2023537048A (ja) 2023-08-30
EP4192941A1 (en) 2023-06-14
KR20230065251A (ko) 2023-05-11
CA3188431A1 (en) 2022-02-10
AU2021320556A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
MX2023001596A (es) Métodos para enriquecer células t diseñadas genéticamente.
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
KR102353924B9 (ko) 수소연료전지 트랙터
WO2021092581A9 (en) Generation of engineered regulatory t cells
NZ734670A (en) Cells for producing recombinant iduronate-2-sulfatase
MX345399B (es) Metodo de cultivo de celulas animales.
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
CA3005639C (en) Energy storage using an rep with an engine
MX2017010859A (es) Metodo de fermentacion mixotrofica para poducir acetona, isopropanol, acido butirico y otros bioproductos, y mezclas de los mismos.
AR120470A1 (es) Métodos para fabricar células t car
MX2023000358A (es) Metodos y composiciones para producir fusosomas virales.
BR112023018844A2 (pt) Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
KR102336152B9 (ko) 수소 연료전지를 동력원으로 하는 콤바인 플랫폼
MX2022012990A (es) Proceso para generar células t autólogas modificadas genéticamente.
BR112022021613A2 (pt) Métodos para gerar células tímicas in vitro
EA201891188A1 (ru) Способ получения метана из диоксида углерода путем совместного культивирования
MX2016014659A (es) Método para obtener un consorcio microbiano para producir hidrógeno e hidrolizados a partir de sustratos complejos.
EA201692263A1 (ru) Совместное культивирование пропионобактерий и дрожжей
MX2021012454A (es) Cromosoma artificial recombinante y su uso.
EA202090440A1 (ru) Улучшенное получение липидов путем ограничения по меньшей мере двух источников лимитирующих питательных веществ
MX2019014088A (es) Metodos de elaboracion y uso de celulas progenitoras mesenquimales embrionarias.
CO2023013211A2 (es) Métodos para almacenar células madre hematopoyéticas
CO2022006782A1 (es) Biorefinería de ciclo cerrado
JP1679212S (ja) 蓄電池用極板
AR113149A1 (es) Producción mejorada de etanol libre de glicerol